A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
NCT01371708
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
283
Enrollment
INDUSTRY
Sponsor class
Conditions
Major Depressive Disorder
Interventions
DRUG:
DVS SR
Sponsor
Pfizer